NCT00706732已完成1 期
A Single-Site, Phase I/II, Double Blinded, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Influenza A/Wyoming/03/2003 Hemagglutinin (AVX502) in Adult Volunteers 65 Years of Age or Older
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 2
- 主要终点
- Evaluate the safety of AVX502 in healthy adult volunteers 65 years of age or older via the frequency of systemic reactogenicity events, local vaccine reactions and Adverse Events
研究概览
简要总结
The objective of this study is to evaluate the safety of the vaccine and the immune response to the vaccine in healthy adult volunteers 65 years of age or older. Volunteers will be assigned by randomization to receive either the vaccine or an inactive substance (placebo) by injections in the arm on two occasions over one month. The study will last approximately 10 months and will have a total of 7 visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 65 years of age or older
- •Good general health without significant physical examination findings or clinically significant abnormal laboratory results
- •Available to participate for entire study period
- •Acceptable laboratory parameters
- •Willingness to have blood stored for up to 10 years for use in additional assays to evaluate immune responses to influenza or the alphavirus vector if such assays become available
- •Willingness to refrain from donating blood while participating in the study
- •Willingness to delay receipt of 2008-2009 licensed influenza vaccination until after completing study visit 6 procedures (study week 8)
- •Signed inform consent obtained before screening and before enrollment
排除标准
- •Venous access deemed inadequate for th phlebotomy demands of the study
- •Receipt of any other vaccine within 30 days prior to enrollment
- •Use of any investigational agent within 30 days prior to enrollment
- •Receipt of immunoglobulin or other blood products within 60 days prior to enrollment
- •Use of cytotoxic medications within 6 months prior to enrollment
- •Use of systemic corticosteroids within 6 months prior to enrollment (except that participants who have completed a course of prednisone, at up to 20 mg per day for up to 7 days, at least 1 month prior to enrollment are eligible for enrollment)
- •History of serious adverse reactions to any vaccines, including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, or abdominal pain
- •History of autoimmune disease or splenectomy
- •History of malignancy within the last 3 years (except that participants with a diagnosis of basal cell carcinoma of the skin are eligible for enrollment)
- •Psychiatric condition that may interfere with the ability to comply with the protocol requirements or to understand informed consent. Specifically excluded are persons with history of psychosis within the past 3 years or history of suicidal attempt or gesture within the past 3 years.
- •History of medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months
- •Any condition which leads the investigator to believe that the particpant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for further participation.
结局指标
主要结局
Evaluate the safety of AVX502 in healthy adult volunteers 65 years of age or older via the frequency of systemic reactogenicity events, local vaccine reactions and Adverse Events
时间窗: 28 weeks
次要结局
- Evaluate the immunogenicity of AVX502 in healthy adult volunteers 65 years of age and older via serum antibody concentration(4 weeks after second dose of vaccine)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.Infection by Streptococcus Group BNCT02459262Minervax ApS240
已完成
1 期
H5N1 (Clade 2) Vaccination of Adults and ElderlyInfluenzaNCT00680069National Institute of Allergy and Infectious Diseases (NIAID)517
已完成
1 期
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's DiseaseAlzheimer DiseaseDementia AlzheimersDementia, MildNCT05328115Alzinova AB33
已完成
3 期
Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult VolunteersInfluenzaNCT01987011Green Cross Corporation420
已完成
1 期
Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast CancerHER2-positive Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerMale Breast CancerNCT01632332Mayo Clinic22